Hematology

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(Constellation) CPI-0610-02 / MANIFEST studyA Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis)Leber, Dr BrianOpen to recruitmentNCT02158858
(Janssen) 54179060CLL3011 / GLOWA Randomized, Open-label Phase 3 study of the Combination of Ibrutinib plus Venetoclax
versus Chlorambucil plus Obinutuzumab for the First-line Treatment of Subjects with Chronic
Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Fraser, Dr GraemeOpen to recruitmentNCT03462719
(Novartis) CINC424D2301 / REACH 3A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients With Corticosteroid-refractory Chronic Graft vs Host Disease After Allogeneic Stem Cell Transplantation (REACH 3)Leber, Dr BrianOpen to recruitmentNCT03112603
(Roche) GO39942 / POLARIXA PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (R-CHP) VERSUS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMAKouroukis, Dr TomOpen to recruitmentNCT03274492
(CCTG) LY.17A Multi-stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell LymphomaFraser, Dr GraemeSuspended/On holdNCT02436707
Download PDF